Bruce Johnson

Bruce Johnson is a highly skilled Pharmaceutical executive with over 30 years of experience in the oncology therapeutic area. He has held various operational and strategic roles in clinical development, US in-line sales and marketing, sales management, launch leadership, new products and portfolio strategy, oncology search and evaluation, and business development.

Throughout his career, Bruce Johnson has been directly responsible for the success of several leading oncology products, including Jakavi, Tasigna, Gleevec/Glivec, Rydapt, Zometa, Sandostatin LAR, and Afinitor. He has led product launches worldwide for oncology indications such as breast, lung, kidney, melanoma, and neuroendocrine tumors, as well as a range of hematologic malignancies.

In his roles, Bruce Johnson led the integration of former GSK oncology assets in Latin America and Canada, built and managed sales and marketing organizations, negotiated partnerships and co-promotion agreements, and spearheaded efforts to acquire new commercial assets.

Bruce Johnson's educational background includes studies in Biochemistry and Molecular Biology at Columbia University in the City of New York, Marketing and Finance at Rutgers Business School, and BA in Microbiology at Miami University.

Currently, Bruce Johnson serves as the Executive VP and Chief Commercial Officer at Cancer Expert Now, Inc. and Noetic Insight, LLC. Prior to this, he held various vice president and executive director positions at major pharmaceutical companies like AbbVie and Novartis. His roles included leading global commercial development, global franchise head for malignant hematology, global disease leader for the leukemia franchise, and commercial head for the oncology business unit in Latin America and Canada.